Teva To Pay $512M To End Provigil Pay-For-Delay Dispute
Teva Pharmaceutical Industries Ltd. and subsidiaries Cephalon Inc. and Barr Pharmaceuticals Inc. have agreed to pay $512 million to settle with the direct purchasers in pay-for-delay litigation over Cephalon's narcolepsy drug...To view the full article, register now.
Already a subscriber? Click here to view full article